Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Cintas Corporation Add to portfolio

INX:CTAS, Jan 22, 05:32 UTC

Latest INX:CTAS News

Filter your feed

Apply Filter

Yesterday


News

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cintas Corp.

CTAS

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cintas Corp. January 21, 2020, 4:00 PM UTC. LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Cintas Corp. (“Cintas” or the “Company”) (NASDAQ: CTAS) investors who purchased securities between March 6, 2017 and November 13, 2019, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. Specifically, Defendants failed to disclose to investors: (1) that Cintas never tracked legacy margins following the G&K acquisition; (2) that the Company has systematically provided guidance with which it would outperform (a "Beat and Raise" scheme); (3) that undisclosed to the investing public, the Company has breached the law multiple times; (4) that as a result of publicly known and undisclosed breaches of law, the Company's Credit Agreement may be jeopardized; and (5) that, as a result of the foregoing, the Company's financial statements were materially false and misleading at all relevant times. Follow us for updates on Twitter: twitter.com/GPM_LLP. If you purchased or otherwise acquired Cintas securities during the Class Period, you may move the Court no later than February 10, 2020 to request appointment as lead plaintiff in this putative class action lawsuit.

Read Full Details

Topics:
  • Business
  • Financial
  • Science

Thursday, January 16


News

CTAS INVESTOR ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Cintas Corporation Investors of Important February 10th Deadline in Securities Class Action Commenced by the Firm – CTAS

CTAS

NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cintas Corporation (CTAS) between March 6, 2017 and November 13, 2019, inclusive (the “Class Period”) of the important February 10, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Cintas investors under the federal securities laws. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Cintas never tracked legacy margins following the G&K acquisition; (2) Cintas has systematically provided guidance with which it would outperform (a “Beat and Raise” scheme); (3) undisclosed to the investing public, Cintas has breached the law multiple times; (4) as a result of publicly known and undisclosed breaches of law, the Company’s Credit Agreement may be jeopardized; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1721.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq.

Read Full Details

Topics:
  • Business
  • Financial
News

Cintas (CTAS) Up 7.1% Since Last Earnings Report: Can It Continue?

CTAS

It has been about a month since the last earnings report for Cintas (CTAS). Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Cintas delivered better-than-expected results for the second quarter of fiscal 2020 (ended Nov 30, 2019). Revenues from the First Aid and Safety Services segment (representing 9.2% of the reported quarter’s net sales) totaled $169.7 million, increasing 10.6% year over year. Organic sales in the quarter increased 10.6%.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, January 15


News

Cintas Co. Expected to Earn Q3 2020 Earnings of $1.96 Per Share (NASDAQ:CTAS) – Slater Sentinel

CTAS

Cintas Co. (NASDAQ:CTAS) – Equities research analysts at Oppenheimer reduced their Q3 2020 earnings per share estimates for shares of Cintas in a research report issued on Wednesday, December 18th, according to Zacks Investment Research. The firm has a market cap of $29.35 billion, a price-to-earnings ratio of 37.45, a P/E/G ratio of 3.04 and a beta of 0.98. Signaturefd LLC now owns 148 shares of the business services provider’s stock valued at $40,000 after purchasing an additional 53 shares in the last quarter. Finally, Capital Investment Advisory Services LLC purchased a new stake in Cintas in the second quarter valued at approximately $52,000.

Read Full Details

Topics:
  • Business
  • Financial
News

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Firm

CTAS

NEW YORK, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Baozun, Inc. (NASDAQ: BZUN), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), Cintas Corporation (NASDAQ: CTAS), and Correvio Pharma Corp. (NASDAQ: CORV). On November 21, 2019, Baozun announced its 3Q19 financial results for the interim period ended September 30, 2019 and provided its 4Q19 financial guidance. The complaint, filed on December 10, 2019, alleges that during the Class Period defendants made false and misleading statements and engaged in a scheme to deceive the market and a course of conduct that artificially inflated the price of Baozun ADRs and operated as a fraud or deceit on Class Period purchasers of Baozun ADRs by misrepresenting the value of the Company’s business and prospects. As Defendants’ misrepresentations and fraudulent conduct became apparent to the market, the price of Baozun ADRs fell precipitously, as the prior artificial inflation came out of the price. As a result of their purchases of Baozun ADRs during the Class Period, Plaintiff and other members of the Class suffered economic losses. For more information on the Baozun class action go to: https://bespc.com/bzun. On March 4, 2019, during Adamas’s Q4 2018 conference call with investors, Adamas walked back its previous prescription growth estimates for GOCOVRI, warned of a continued slow-down in GOCOVRI prescriptions, and refused to make further predictions about GOCOVRI’s ability to achieve a sizeable market share.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, January 14


News

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cintas Corp.

CTAS

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cintas Corp. January 14, 2020, 4:00 PM UTC. LOS ANGELES, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Cintas Corp. (“Cintas” or the “Company”) (NASDAQ: CTAS) investors who purchased securities between March 6, 2017 and November 13, 2019, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. Specifically, Defendants failed to disclose to investors: (1) that Cintas never tracked legacy margins following the G&K acquisition; (2) that the Company has systematically provided guidance with which it would outperform (a "Beat and Raise" scheme); (3) that undisclosed to the investing public, the Company has breached the law multiple times; (4) that as a result of publicly known and undisclosed breaches of law, the Company's Credit Agreement may be jeopardized; and (5) that, as a result of the foregoing, the Company's financial statements were materially false and misleading at all relevant times. Follow us for updates on Twitter: twitter.com/GPM_LLP. If you purchased or otherwise acquired Cintas securities during the Class Period, you may move the Court no later than February 10, 2020 to request appointment as lead plaintiff in this putative class action lawsuit.

Read Full Details

Topics:
  • Business
  • Financial
  • Science

Monday, January 13


News

William Blair Research Analysts Raise Earnings Estimates for Cintas Co. (NASDAQ:CTAS) – Riverton Roll

CTAS

Cintas Co. (NASDAQ:CTAS) – Investment analysts at William Blair raised their FY2020 EPS estimates for Cintas in a report released on Wednesday, December 18th, Zacks Investment Research reports. William Blair analyst T. Mulrooney now expects that the business services provider will earn $8.87 per share for the year, up from their prior estimate of $8.57. Finally, Credit Suisse Group upped their price target on Cintas from $195.00 to $225.00 and gave the stock a “neutral” rating in a report on Wednesday, September 25th. Cintas announced that its board has initiated a stock buyback plan on Tuesday, October 29th that permits the company to buyback $1.00 billion in outstanding shares.

Read Full Details

Topics:
  • Business
  • Financial

Sunday, January 12


News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cintas Corporation - CTAS

CTAS

NEW YORK, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cintas Corporation ("Cintas" or the "Company") (NASDAQ:CTAS). On November 13, 2019, Spruce Point Capital Management ("Spruce Point") issued a report on Cintas claiming to "have evidence that Cintas' Fire Protection Services was charged with fraud and is causing a public safety hazard by having workers conduct fire and safety inspections without proper licenses or permits, and falsifying inspections." Spruce Point additionally stated that "Cintas is facing financial strain in its core uniform rental business from its 2017 levered acquisition of G&K [Services, Inc.] for $2.1 bn," asserting that "it appears management may have suppressed G&K revenue and misguided expenses." Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct.

Read Full Details

Topics:
  • Business
  • Financial

Friday, January 10


News

Cintas (CTAS) Hits 52-Week High, Can the Run Continue?

CTAS

Shares have been on the move with the stock up 7.8% over the past month. Cintas has gained 3.8% since the start of the year compared to the 0.4% move for the Zacks Industrial Products sector and the 3.7% return for the Zacks Uniform and Related industry. What's Driving the Outperformance? In its last earnings report on December 17, 2019, Cintas reported EPS of $2.27 versus consensus estimate of $2.04 while it beat the consensus revenue estimate by 1.19%. For the current fiscal year, Cintas is expected to post earnings of $8.79 per share on $7.33 billion in revenues. We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Cintas currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Cintas fits the bill.

Read Full Details

Topics:
  • Business
  • Financial
News

Cintas Corporation (CTAS) Climbs 2.44% Today: Breaking Down The Root Causes

CTAS

CTAS shares had a relatively better volume day versus average trading capacity of 551.79 thousand shares, but with a 87.08 million float and a 2.3% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for CTAS stock indicates that the average analyst price target is $284.8 per share. During the recent trading session for Cintas Corporation (NASDAQ:CTAS), the company witnessed their stock rise $10.39 over a week and surge $25.28 from the price 20 days ago. When compared to their established 52-week high of $282.89, the high they recorded in their recent session happens to be higher. Technical chart claims that Cintas Corporation (CTAS) would settle between $277.77/share to $280.25/share level. However, if the stock price goes below the $270.85 mark, then the market for Cintas Corporation becomes much weaker. If that happens, the stock price might even plunge as low as $266.42 for its downside target.

Read Full Details

Topics:
  • Business
  • Financial